Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Gilead (GILD) Announces Top-Line Results From NASH Study

Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.

Mark Vickery headshot

Top Research Reports for Microsoft, Wells Fargo & Chevron

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Wells Fargo (WFC) and Chevron (CVX).

Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies

Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.

Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

Kinjel Shah headshot

4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

Mark Vickery headshot

Top Analyst Reports for Microsoft, Novartis & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Novo Nordisk (NVO).

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy

The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy

Mark Vickery headshot

Top Analyst Reports for Citigroup, Novo Nordisk & BP

Today's Research Daily features new research reports on 16 major stocks, including Citigroup (C), Novo Nordisk (NVO) and BP (BP).

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices

The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices

Mark Vickery headshot

Top Analyst Reports for Intel, Oracle & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Oracle (ORCL) and Novo Nordisk (NVO).

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

Kinjel Shah headshot

Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

bluebird Inks Genome Editing Research Deal With Novo Nordisk

bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.

Novo Nordisk Focuses on Pipeline Development Amid Competition

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

SNY or NVO: Which Is the Better Value Stock Right Now?

SNY vs. NVO: Which Stock Is the Better Value Option?